- Influenzavirus B
name = Orthomyxoviridae
virus_group = v
familia = "Orthomyxoviridae"
subdivision_ranks = Genera
subdivision = "
Influenzavirus B is a genus in the
virusfamily Orthomyxoviridae. The only species in this genus is called "Influenza B virus".
Influenza B viruses are only known to infect
humans and seals,cite journal | author = Osterhaus AD, Rimmelzwaan GF, Martina BE, Bestebroer TM, Fouchier RA | title = Influenza B virus in seals | journal = Science | volume = 288 | issue = 5468 | pages = 1051–3 | year = 2000 | pmid = 10807575 | doi = | issn = ] giving them influenza. This limited host range is apparently responsible for the lack of Influenzavirus B caused influenza pandemics in contrast with those caused by the morphologically similar Influenzavirus Aas both mutate by both genetic drift and reassortment.cite journal | author = Hay AJ, Gregory V, Douglas AR, Lin YP | title = The evolution of human influenza viruses | journal = Philos. Trans. R. Soc. Lond., B, Biol. Sci. | volume = 356 | issue = 1416 | pages = 1861–70 | year = 2001 | pmid = 11779385 | doi = 10.1098/rstb.2001.0999] cite journal | author = Matsuzaki Y, Sugawara K, Takashita E, Muraki Y, Hongo S, Katsushima N, Mizuta K, Nishimura H | title = Genetic diversity of influenza B virus: the frequent reassortment and cocirculation of the genetically distinct reassortant viruses in a community | journal = J. Med. Virol. | volume = 74 | issue = 1 | pages = 132–40 | year = 2004 | pmid = 15258979 | doi = 10.1002/jmv.20156] cite journal | author = Lindstrom SE, Hiromoto Y, Nishimura H, Saito T, Nerome R, Nerome K | title = Comparative analysis of evolutionary mechanisms of the hemagglutinin and three internal protein genes of influenza B virus: multiple cocirculating lineages and frequent reassortment of the NP, M, and NS genes | journal = J. Virol. | volume = 73 | issue = 5 | pages = 4413–26 | year = 1999 | pmid = 10196339 | doi = ]
Further diminishing the impact of this virus "in man, influenza B viruses evolve slower than A viruses and faster than C viruses".cite journal | author = Yamashita M, Krystal M, Fitch WM, Palese P | title = Influenza B virus evolution: co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses | journal = Virology | volume = 163 | issue = 1 | pages = 112–22 | year = 1988 | pmid = 3267218 | doi = ] Influenzavirus B mutates at a rate 2-3 times lower than type A. [cite journal | author = Nobusawa E, Sato K | title = Comparison of the mutation rates of human influenza A and B viruses. | journal = J Virol | volume = 80 | issue = 7 | pages = 3675–8 | year = 2006 | month=Apr | pmid = 16537638 | doi = 10.1128/JVI.80.7.3675-3678.2006] However, influenza B mutates enough that lasting immunity is not possible. For example at the U.S.'s
Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research's Vaccines and Related Biological Products Advisory Committee's 101st meeting of February 16 2005, an extensive discussion and vote was held concerning next year's flu vaccine virus selection including which influenza B strain to use in the formulation of the flu vaccine:
"For Influenza B, the question was asked: are there new strains present? And the answer was yes, and in 2004, the majority of the viruses were similar to a strain called B/Shanghai/361/2002, which is from the so-called B/Yamagata/1688
hemagglutininlineage. That lineage was not the one that was being used in the vaccine that was current last year. In a minority of the strains that were found during the epidemiological studies were similar to the strain that was in the vaccine for last year, which was B/Hong Kong/330/2001, which belongs to the HA lineage that we represent with the strain B/Victoria/287. In answer to the question were these new viruses spreading, the answer, of course, is definitely yes. The Fujian-like viruses had become widespread around the world and were predominant everywhere, and these B/Shanghai-like strains at the time we were holding this meeting in February were predominant not only in North America and the United States, but also in Asia and Europe." [Transcript of U.S. FDA Center for Biologics Evaluation and Research Vaccines and Related Biological Products Advisory Committee's 101st meeting of February 16, 2005. [http://origin.www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4087T1.DOC origin.www.fda.gov DOC format] [http://www.google.com/search?q=cache:8hPXwU4pfyAJ:origin.www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4087T1.DOC+CDC+H5N1+research+%22two+clades%22&hl=en&gl=us&ct=clnk&cd=18 Google provided HTML format] ]
The Influenza B virus
capsidis enveloped while its virionconsists of an envelope, a matrix protein, a nucleoprotein complex, a nucleocapsid, and a polymerasecomplex. It is sometimes spherical and sometimes filamentous. Its 500 or so surface projections are made of hemagglutinin and neuraminidase.cite web | url = http://www.ncbi.nlm.nih.gov/ICTVdb/ICTVdB/00.046.0.04.htm | title = ICTVdB Virus Description - 00.046.0.04. Influenzavirus B | accessdate = 2007-09-15 | author = Büchen-Osmond, C. (Ed) | date = 2006 | format = | work = ICTVdB - The Universal Virus Database, version 4 | publisher = Columbia University, New York, USA ]
The Influenza B virus genome is 14648
nucleotideslong and consists of eight segments of linear negative-sense, single-stranded RNA. The multipartite genome is encapsidated, each segment in a separate nucleocapsid, and the nucleocapsids are surrounded by one envelope.
Wikimedia Foundation. 2010.